Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20056417 | 0.89 | MAPT (0.58) | KDM4EMAPTRAB9ANPC1MEN1 | |
| SCHEMBL16385162 | 0.84 | RAB9A (0.59) | KDM4EMAPTRAB9ANPC1MEN1 | |
| SCHEMBL16385399 | 0.79 | KDM4E (0.49) | KDM4EMAPTRAB9ANPC1MEN1 | |
| SCHEMBL16385157 | 0.78 | MAPT (0.48) | KDM4EMAPTRAB9ANPC1MEN1 | |
| SCHEMBL16385301 | 0.78 | ESR2 (0.56) | MEN1KMT2AJAK2 | |
| SCHEMBL17744653 | 0.77 | KMO (0.51) | KDM4EMAPTRAB9ANPC1MEN1 | |
| SCHEMBL13511832 | 0.76 | MAPT (0.49) | KDM4EMAPTRAB9ANPC1MEN1 | |
| SCHEMBL2810314 | 0.76 | DYRK1A (0.50) | KDM4EMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL16385231 | 0.75 | KMO (0.52) | KDM4ERAB9ANPC1MEN1KMT2A | |
| SCHEMBL17144996 | 0.74 | KDM4E (0.65) | KDM4EMAPTRAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020715-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-9888688-B2 | Tetrazolinone compounds and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9888688-B2 | Tetrazolinone compounds and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-02 | — | — | US | disclosed |
| WO-2015005499-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | 住友化学株式会社 (JP) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SOD1, UQCRB, MT-CO1 | KDM4E 3517/4885MAPT 3902/4885RAB9A 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.